Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II)

Inclusion Criteria: 1. Males or females \> 20 and \< 80 years of age 2. Significant multi-vessel coronary artery disease not amenable to percutaneous or surgical revascularization 3. CCS Angina Functional Class II-IV and/or NYHA Stages of Heart Failure Class II or III 4. On maximal medical therapy for anginal symptoms and/or heart failure symptoms 5. Hemodynamic stability (SBP ≥ 90 mm/Hg, HR \<110) 6. Ejection fraction ≥ 20% and ≤ 45% 7. Inducible ischemia using an objective assessment of ischemia within 1 year of screening (i.e. exercise ECG changes, SPECT) 8. Left ventricular wall thickness ≥ 8 mm at the target site for cell injection Exclusion Criteria: 1. Atrial fibrillation or flutter without a pace maker that guarantees a stable heart rate 2. Unstable angina 3. LV thrombus, as documented by echocardiography 4. Planned staged treatment of CAD or other intervention on the heart 5. Platelet count \< 100,000/mm3 6. WBC \< 2,000/mm3 7. TIA or stroke within 90 days prior to randomization 8. ICD shock within 30 days prior to randomization 9. Any condition requiring immunosuppressive medication 10. A high-risk acute coronary syndrome (ACS) or a myocardial infarction in the 60 days prior to randomization 11. Revascularization within 60 days prior to randomization 12. Inability to walk on a treadmill except for class IV angina patients who will be evaluated separately 13. Hepatic dysfunction, as defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 1.5 times the upper limit of normal range (x ULN) 14. Hemoglobin ≤ 10.0 g/dL